The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Treatment of renal cell carcinoma: Current status and future directions
Open accessAbstract
Answer questions and earn CME/CNE Over the past 12 years, medical treatment for renal cell carcinoma (RCC) has transitioned from a nonspecific immune approach (in the cytokine era), to targeted therapy against vascular endothelial growth factor (VEGF), and now to novel immunotherapy agents. Multiple agents—including molecules against vascular endothelial growth factor, platelet‐derived growth factor, and related receptors; inhibitors of other targets, such as the mammalian target of rapamycin and the MET and AXL tyrosine‐protein kinase receptors; and an immune‐checkpoint inhibitor—have been approved based on significant activity in patients with advanced RCC. Despite these advances, important questions remain regarding biomarkers of efficacy, patient selection, and the optimal combination and sequencing of agents. The purpose of this review is to summarize present management and future directions in the treatment of metastatic RCC. CA Cancer J Clin 2017;67:507‐524. © 2017 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,781
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,502
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.029 · Cited by 3,086
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Sternberg, C. N., Davis, I. D., Mardiak, J., Szczylik, C., Lee, E., Wagstaff, J., Barrios, C. H., Salman, P., Gladkov, O. A., Kavina, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.9764 · Cited by 2,471
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Heng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133
Self-citationPazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Cella, D., Reeves, J., Hawkins, R., Guo, J., Nathan, P., Staehler, M., de Souza, P., Merchan, J. R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303989 · Cited by 1,923
Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, M. D., Gorbunova, V. A., Gore, M. E., Rusakov, I. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,840
Self-citationFlanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Munshi, N., & Crawford, E. D. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003013 · Cited by 1,715
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Self-citationCombining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
Mickisch, G., Garin, A., van Poppel, H., de Prijck, L., & Sylvester, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06103-7 · Cited by 1,410
Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,391
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
The Cancer Genome Atlas Research Network (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505917 · Cited by 1,336
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Choueiri, T. K., Escudier, B., Powles, T., Mainwaring, P. N., Rini, B. I., Donskov, F., Hammers, H., Hutson, T. E., Lee, J.-L., Peltola, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510016 · Cited by 1,239
Self-citationFRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64153-5 · Cited by 1,175
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2010) · Cancer · doi:10.1002/cncr.25219 · Cited by 1,139
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Staehler, M., Negrier, S., Chevreau, C., Desai, A. A., Rolland, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5511 · Cited by 1,085
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia
Srigley, J. R., Delahunt, B., Eble, J. N., Egevad, L., Epstein, J. I., Grignon, D., Hes, O., Moch, H., Montironi, R., Tickoo, S. K., et al. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318299f2d1 · Cited by 1,047
Choueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F., Roth, B. J., Peltola, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 958
Self-citationMotzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T., Jassem, J., Zolnierek, J., Maroto, J. P., Mellado, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00290-9 · Cited by 945
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Self-citationLeibovich, B. C., Blute, M. L., Cheville, J. C., Lohse, C. M., Frank, I., Kwon, E. D., Weaver, A. L., Parker, A. S., & Zincke, H. (2003) · Cancer · doi:10.1002/cncr.11234 · Cited by 837
Walter, S., Weinschenk, T., Stenzl, A., Zdrojowy, R., Pluzanska, A., Szczylik, C., Staehler, M., Brugger, W., Dietrich, P.-Y., Mendrzyk, R., et al. (2012) · Nature Medicine · doi:10.1038/nm.2883 · Cited by 788
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
Ravaud, A., Motzer, R. J., Pandha, H. S., George, D. J., Pantuck, A. J., Patel, A., Chang, Y.-H., Escudier, B., Donskov, F., Magheli, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611406 · Cited by 782
Motzer, R. J., Escudier, B., Tomczak, P., Hutson, T. E., Michaelson, M. D., Negrier, S., Oudard, S., Gore, M. E., Tarazi, J., Hariharan, S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70093-7 · Cited by 745
Self-citationImproved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System
Zisman, A., Pantuck, A. J., Dorey, F., Said, J. W., Shvarts, O., Quintana, D., Gitlitz, B. J., deKernion, J. B., Figlin, R. A., & Belldegrun, A. S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1649 · Cited by 729
Choueiri, T. K., Halabi, S., Sanford, B. L., Hahn, O., Michaelson, M. D., Walsh, M. K., Feldman, D. R., Olencki, T., Picus, J., Small, E. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7398 · Cited by 720
Haas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., Atkins, M. B., Pins, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00559-6 · Cited by 630
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors
Nickerson, M. L., Jaeger, E., Shi, Y., Durocher, J. A., Mahurkar, S., Zaridze, D., Matveev, V., Janout, V., Kollarova, H., Bencko, V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4921 · Cited by 588
Resection of metastatic renal cell carcinoma.
Kavolius, J. P., Mastorakos, D. P., Pavlovich, C., Russo, P., Burt, M. E., & Brady, M. S. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2261 · Cited by 559
McDermott, D. F., Sosman, J. A., Sznol, M., Massard, C., Gordon, M. S., Hamid, O., Powderly, J. D., Infante, J. R., Fassò, M., Wang, Y. V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7421 · Cited by 557
Shuch, B., Amin, A., Armstrong, A. J., Eble, J. N., Ficarra, V., Lopez-Beltran, A., Martignoni, G., Rini, B. I., & Kutikov, A. (2015) · European Urology · doi:10.1016/j.eururo.2014.04.029 · Cited by 531
Self-citationOyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L. D., Carbone, D. P., & Gabrilovich, D. I. (1998) · PubMed · Cited by 530
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., & Gabrilovich, D. I. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.3.1224 · Cited by 481
Choueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., Bukowski, R. M., Rini, B. I., Srinivas, S., Stein, M. N., Adams, L. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3383 · Cited by 463
Self-citationMotzer, R. J., Nosov, D., Eisen, T., Bondarenko, I., Lesovoy, V., Lipatov, O., Tomczak, P., Lyulko, O., Alyasova, A., Harza, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.4940 · Cited by 445
Fisher, R. I., Rosenberg, S. A., & Fyfe, G. (2000) · PubMed · Cited by 439
Escudier, B., Porta, C., Bono, P., Powles, T., Eisen, T., Sternberg, C. N., Gschwend, J. E., De Giorgi, U., Parikh, O., Hawkins, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.8267 · Cited by 436
Jocham, D., Richter, A., Hoffmann, L., Iwig, K., Fahlenkamp, D., Zakrzewski, G., Schmitt, E., Dannenberg, T., Lehmacher, W., von Wietersheim, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15590-6 · Cited by 434
Motzer, R. J., Barrios, C. H., Kim, T. M., Falcon, S., Cosgriff, T., Harker, W. G., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S. Y., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.6911 · Cited by 432
Survival after complete surgical resection of multiple metastases from renal cell carcinoma
Alt, A. L., Boorjian, S. A., Lohse, C. M., Costello, B. A., Leibovich, B. C., & Blute, M. L. (2011) · Cancer · doi:10.1002/cncr.25836 · Cited by 426
Armstrong, A. J., Halabi, S., Eisen, T., Broderick, S., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., Picus, J., Hawkins, R. E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00515-x · Cited by 426
Patard, J.-J., Kim, H. L., Lam, J. S., Dorey, F. J., Pantuck, A. J., Zisman, A., Ficarra, V., Han, K.-R., Cindolo, L., De La Taille, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.104 · Cited by 423
Hutson, T. E., Lesovoy, V., Al-Shukri, S., Stus, V. P., Lipatov, O. N., Bair, A. H., Rosbrook, B., Chen, C., Kim, S., & Vogelzang, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70465-0 · Cited by 404
Hutson, T. E., Escudier, B., Esteban, E., Bjarnason, G. A., Lim, H. Y., Pittman, K. B., Senico, P., Niethammer, A., Lu, D. R., Hariharan, S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3961 · Cited by 404
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
Zhou, L., Liu, X.-D., Sun, M., Zhang, X., German, P., Bai, S., Ding, Z., Tannir, N., Wood, C. G., Matin, S. F., et al. (2016) · Oncogene · doi:10.1038/onc.2015.343 · Cited by 395
Ko, J. J., Xie, W., Kroeger, N., Lee, J.-L., Rini, B. I., Knox, J. J., Bjarnason, G. A., Srinivas, S., Pal, S. K., Yuasa, T., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71222-7 · Cited by 382
Self-citationVEGF as a Mediator of Tumor-Associated Immunodeficiency
Ohm, J. E., & Carbone, D. P. (2001) · Immunologic Research · doi:10.1385/ir:23:2-3:263 · Cited by 371
Tannir, N. M., Jonasch, E., Albiges, L., Altinmakas, E., Ng, C. S., Matin, S. F., Wang, X., Qiao, W., Dubauskas Lim, Z., Tamboli, P., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.10.049 · Cited by 364
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma
Chen, F., Zhang, Y., Şenbabaoğlu, Y., Ciriello, G., Yang, L., Reznik, E., Shuch, B., Micevic, G., De Velasco, G., Shinbrot, E., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.02.024 · Cited by 359
Wood, C., Srivastava, P., Bukowski, R., Lacombe, L., Gorelov, A. I., Gorelov, S., Mulders, P., Zielinski, H., Hoos, A., Teofilovici, F., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60697-2 · Cited by 332
Messing, E. M., Manola, J. B., Wilding, G., PROPERT, K. J., Fleischmann, J. D., Crawford, E. D., Pontes, J. E., Hahn, R. G., & Trump, D. L. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.005 · Cited by 309
Molecular Genetics of Clear-Cell Renal Cell Carcinoma
Brugarolas, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2003 · Cited by 306
PD-L1 expression in nonclear-cell renal cell carcinoma
Choueiri, T. K., Fay, A. P., Gray, K. P., Callea, M., Ho, T. H., Albiges, L., Bellmunt, J., Song, J., Carvo, I., Lampron, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu445 · Cited by 302
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282
Novel immunotherapies in lymphoid malignancies
Batlevi, C. L., Matsuki, E., Brentjens, R. J., & Younes, A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.187 · Cited by 260
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
Rini, B. I., Dorff, T. B., Elson, P., Rodriguez, C. S., Shepard, D., Wood, L., Humbert, J., Pyle, L., Wong, Y.-N., Finke, J. H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30196-6 · Cited by 257
Self-citationRini, B., Goddard, A., Knezevic, D., Maddala, T., Zhou, M., Aydin, H., Campbell, S., Elson, P., Koscielny, S., Lopatin, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70167-1 · Cited by 254
Self-citationOtt, P. A., Hodi, F. S., & Buchbinder, E. I. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00202 · Cited by 242
Amin, A., Plimack, E. R., Infante, J. R., Ernstoff, M. S., Rini, B. I., McDermott, D. F., Knox, J. J., Pal, S. K., Voss, M. H., Sharma, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5010 · Cited by 233
Self-citationRini, B. I., Melichar, B., Ueda, T., Grünwald, V., Fishman, M. N., Arranz, J. A., Bair, A. H., Pithavala, Y. K., Andrews, G. I., Pavlov, D., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70464-9 · Cited by 231
Self-citationHanna, N., Sun, M., Meyer, C. P., Nguyen, P. L., Pal, S. K., Chang, S. L., de Velasco, G., Trinh, Q.-D., & Choueiri, T. K. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7931 · Cited by 229
Kwiatkowski, D. J., Choueiri, T. K., Fay, A. P., Rini, B. I., Thorner, A. R., de Velasco, G., Tyburczy, M. E., Hamieh, L., Albiges, L., Agarwal, N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2631 · Cited by 228
Self-citationAtzpodien, J., Kirchner, H., Jonas, U., Bergmann, L., Schott, H., Heynemann, H., Fornara, P., Loening, S. A., Roigas, J., Müller, S. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.155 · Cited by 223
Rini, B. I., Stenzl, A., Zdrojowy, R., Kogan, M., Shkolnik, M., Oudard, S., Weikert, S., Bracarda, S., Crabb, S. J., Bedke, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30408-9 · Cited by 220
Self-citationAlfaro, C., Suarez, N., Gonzalez, A., Solano, S., Erro, L., Dubrot, J., Palazon, A., Hervas-Stubbs, S., Gurpide, A., Lopez-Picazo, J. M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604965 · Cited by 214
Voss, M. H., Hakimi, A. A., Pham, C. G., Brannon, A. R., Chen, Y.-B., Cunha, L. F., Akin, O., Liu, H., Takeda, S., Scott, S. N., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2345 · Cited by 214
Amin, A., Dudek, A. Z., Logan, T. F., Lance, R. S., Holzbeierlein, J. M., Knox, J. J., Master, V. A., Pal, S. K., Miller, W. H., Karsh, L. I., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0055-3 · Cited by 205
STEPHENSON, A. J., CHETNER, M. P., ROURKE, K., GLEAVE, M. E., SIGNAEVSKY, M., PALMER, B., KUAN, J., BROCK, G. B., & TANGUAY, S. (2004) · Journal of Urology · doi:10.1097/01.ju.0000132126.85812.7d · Cited by 195
Recent Progress in the Management of Advanced Renal Cell Carcinoma
Garcia, J. A., & Rini, B. I. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.2.112 · Cited by 181
Self-citationWalther, M., Alexander, R. B., Weiss, G. H., Venzon, D., Berman, A., Pass, H. I., Linehan, W. M., & Rosenberg, S. A. (1993) · Urology · doi:10.1016/0090-4295(93)90612-e · Cited by 175
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
Choueiri, T. K., Pal, S. K., McDermott, D. F., Morrissey, S., Ferguson, K. C., Holland, J., Kaelin, W. G., & Dutcher, J. P. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu184 · Cited by 163
Rini, B. I., Stein, M. N., Shannon, P., Eddy, S., Tyler, A. J., Stephenson, J., Catlett, L., Huang, B., Healey, D. I., & Gordon, M. S. (2010) · Cancer · doi:10.1002/cncr.25639 · Cited by 155
Self-citationAdjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma
Chamie, K., Donin, N. M., Klöpfer, P., Bevan, P., Fall, B., Wilhelm, O. G., Störkel, S., SAID, J. W., Gambla, M., Hawkins, R. E., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4419 · Cited by 147
The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy
Clark, P. E. (2009) · Kidney International · doi:10.1038/ki.2009.296 · Cited by 143
D. G. C. I. N. (German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group), Atzpodien, J., Kirchner, H. H., Illiger, H. J., Metzner, B., Ukena, D., Schott, H., Funke, P.-J., Gramatzki, M., von Jürgenson, S., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2076 · Cited by 133
Motzer, R. J., Hutson, T. E., Ren, M., Dutcus, C. E., & Larkin, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00543-4 · Cited by 124
Adjuvant Therapy in Renal Cell Carcinoma—Past, Present, and Future
Janowitz, T., Welsh, S. J., Zaki, K. A., Mulders, P., & Eisen, T. G. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.05.004 · Cited by 117
Medical treatment of renal cancer: new horizons
Greef, B., & Eisen, T. G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.230 · Cited by 115
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
Carlo, M. I., Voss, M. H., & Motzer, R. J. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.103 · Cited by 95
Petrelli, F., Coinu, A., Vavassori, I., Cabiddu, M., Borgonovo, K., Ghilardi, M., Lonati, V., & Barni, S. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.04.001 · Cited by 85
Pichler, M., Hutterer, G. C., Chromecki, T. F., Jesche, J., Kampel‐Kettner, K., Rehak, P., Pummer, K., & Zigeuner, R. E. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.07.034 · Cited by 76
McDermott, D. F., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B. J., Fong, L. H., Joseph, R. W., Pal, S. K., Sznol, M., Hainsworth, J. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.6_suppl.431 · Cited by 70
Self-citationPrecision medicine from the renal cancer genome
Riazalhosseini, Y., & Lathrop, M. G. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.133 · Cited by 69
Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future
Pal, S. K., & Haas, N. B. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0105 · Cited by 64
Hutson, T. E., Al-Shukri, S. K., Stus, V. P., Lipatov, O. N., Shparyk, Y. V., Bair, A. H., Rosbrook, B., Andrews, G. I., & Vogelzang, N. J. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.05.008 · Cited by 61
A four-gene signature predicts survival in clear-cell renal-cell carcinoma
Dai, J., Lu, Y., Wang, J., Yang, L., Han, Y., Wang, Y., Yan, D., Ruan, Q., & Wang, S. (2016) · Oncotarget · doi:10.18632/oncotarget.12631 · Cited by 45
Choueiri, T. K., Larkin, J., Oya, M., Thistlethwaite, F. C., Martignoni, M., Nathan, P., Powles, T. B., McDermott, D. F., Robbins, P. B., Chism, D. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4504 · Cited by 39
Self-citationUnderstanding the natural biology of kidney cancer: implications for targeted cancer therapy.
Klatte, T., Pantuck, A. J., Kleid, M. D., & Belldegrun, A. S. (2007) · Europe PMC (PubMed Central) · Cited by 37
Adler, A. G., GILLON, G., Lurie, H., et al. (1987) · PubMed · Cited by 37
Collinson, F. J., Gregory, W. M., McCabe, C., Howard, H., Lowe, C., Potrata, D., Tubeuf, S., Hanlon, P., McParland, L., Wah, T. M., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-598 · Cited by 34
A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors
Taylor, M. H., Dutcus, C. E., Schmidt, E. V., Bagulho, T., Li, D., Shumaker, R. C., & Rasco, D. W. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw373.04 · Cited by 33
Motzer, R. J., Haas, N. B., Donskov, F. N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4507 · Cited by 33
Atkins, M. B., Plimack, E. R., Puzanov, I. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw373.01 · Cited by 31
Beisland, C., Guðbrandsdottir, G., Reisæter, L. A. R., Bostad, L. H., Wentzel‐Larsen, T., & Hjelle, K. M. (2014) · Scandinavian Journal of Urology · doi:10.3109/21681805.2014.980844 · Cited by 27
Non-clear cell renal cell carcinoma, part 1: histology.
Valença, L. B., Hirsch, M. S., Choueiri, T. K., & Harshman, L. C. (2015) · PubMed · Cited by 16
McDermott, D. F., Infante, J. R., Chowdhury, S., Voss, M. H., Motzer, R. J., Perini, R. F., Morosky, A., Zheng, F., White, B. C., Wang, Q., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31440-x · Cited by 14
Self-citationFuture Challenges for Drug Development in Renal Cell Carcinoma
Rini, B. I., & Vogelzang, N. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0673 · Cited by 8
Self-citationWeinstock, M., & McDermott, D. F. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e291 · Cited by 4
Harrell, F., Jr. (1996) · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
Cited by
Zhu, C., Wei, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1090-3 · Cited by 488
The Metabolic Basis of Kidney Cancer
Linehan, W. M., Schmidt, L. S., Crooks, D. R., Wei, D., Srinivasan, R., Lang, M., & Ricketts, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1354 · Cited by 306
Immune infiltration in renal cell carcinoma
Zhang, S., Zhang, E., Long, J., Hu, Z., Peng, J., Liu, L., Tang, F., Li, L., Ouyang, Y., & Zeng, Z. (2019) · Cancer Science · doi:10.1111/cas.13996 · Cited by 305
Single-cell multiomics analysis reveals regulatory programs in clear cell renal cell carcinoma
Long, Z., Sun, C., Tang, M., Wang, Y., Ma, J., Yu, J., Wei, J., Ma, J., Wang, B., Xie, Q., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00415-0 · Cited by 109
Su, Y., Zhang, T., Lu, J., Qian, L., Fei, Y., Zhang, L., Fan, S., Zhou, J., Tang, J., Chen, H., et al. (2023) · Cells · doi:10.3390/cells12010180 · Cited by 20
Metadata
- Authors
- Barata, P. C., & Rini, B. I.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2017-09-29
- Volume
- 67
- Issue
- 6
- Pages
- 507-524
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W2757487320
- Cited by
- 831
- References
- 112
- FWCI
- 38.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.